CL2012001547A1 - Anticuerpo ligante de csf-1r humano; composicion farmaceutica que lo comprende; acido nucleico que lo codifica; vector de expresion recombinante; celula procariotica o eucariotica transformada; metodo de produccion; y su uso para tratar cancer. - Google Patents
Anticuerpo ligante de csf-1r humano; composicion farmaceutica que lo comprende; acido nucleico que lo codifica; vector de expresion recombinante; celula procariotica o eucariotica transformada; metodo de produccion; y su uso para tratar cancer.Info
- Publication number
- CL2012001547A1 CL2012001547A1 CL2012001547A CL2012001547A CL2012001547A1 CL 2012001547 A1 CL2012001547 A1 CL 2012001547A1 CL 2012001547 A CL2012001547 A CL 2012001547A CL 2012001547 A CL2012001547 A CL 2012001547A CL 2012001547 A1 CL2012001547 A1 CL 2012001547A1
- Authority
- CL
- Chile
- Prior art keywords
- encodes
- nucleic acid
- pharmaceutical composition
- production
- expression vector
- Prior art date
Links
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 210000003527 eukaryotic cell Anatomy 0.000 title 1
- 239000013604 expression vector Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 210000001236 prokaryotic cell Anatomy 0.000 title 1
- 238000003259 recombinant expression Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09015310 | 2009-12-10 | ||
| EP10173407 | 2010-08-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012001547A1 true CL2012001547A1 (es) | 2012-10-12 |
Family
ID=43735019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012001547A CL2012001547A1 (es) | 2009-12-10 | 2012-06-08 | Anticuerpo ligante de csf-1r humano; composicion farmaceutica que lo comprende; acido nucleico que lo codifica; vector de expresion recombinante; celula procariotica o eucariotica transformada; metodo de produccion; y su uso para tratar cancer. |
Country Status (36)
| Country | Link |
|---|---|
| US (10) | US8999327B2 (es) |
| EP (2) | EP2510010B1 (es) |
| JP (3) | JP5677451B2 (es) |
| KR (1) | KR101434070B1 (es) |
| CN (2) | CN102791738B (es) |
| AR (1) | AR079333A1 (es) |
| AU (2) | AU2010329934B2 (es) |
| BR (1) | BR112012013717B1 (es) |
| CA (1) | CA2780692C (es) |
| CL (1) | CL2012001547A1 (es) |
| CO (1) | CO6541621A2 (es) |
| CR (1) | CR20120215A (es) |
| CY (1) | CY1117331T1 (es) |
| DK (2) | DK2949670T3 (es) |
| EC (1) | ECSP12011964A (es) |
| ES (2) | ES2722300T3 (es) |
| HK (1) | HK1219739A1 (es) |
| HR (2) | HRP20160131T1 (es) |
| HU (2) | HUE044179T2 (es) |
| IL (1) | IL219595A (es) |
| LT (1) | LT2949670T (es) |
| MA (1) | MA34780B1 (es) |
| MX (2) | MX2012006553A (es) |
| MY (1) | MY159679A (es) |
| NZ (1) | NZ599516A (es) |
| PE (1) | PE20121398A1 (es) |
| PH (1) | PH12012500881A1 (es) |
| PL (2) | PL2949670T3 (es) |
| PT (2) | PT2949670T (es) |
| RS (2) | RS54596B1 (es) |
| RU (1) | RU2565541C2 (es) |
| SG (1) | SG181589A1 (es) |
| SI (2) | SI2510010T1 (es) |
| TW (1) | TWI422388B (es) |
| WO (1) | WO2011070024A1 (es) |
| ZA (1) | ZA201203782B (es) |
Families Citing this family (261)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| US9221910B2 (en) | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| BR112012020372A8 (pt) | 2010-03-05 | 2018-01-02 | Hoffmann La Roche | anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante |
| MX2012012790A (es) | 2010-05-04 | 2013-02-15 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| US9243066B2 (en) | 2011-07-18 | 2016-01-26 | University Of Melbourne | Use of M-CSF antibodies in the treatment of osteoarthritis or pain |
| US9139652B2 (en) * | 2011-10-21 | 2015-09-22 | Transgene Sa | Method for increasing M1 macrophages in a patient |
| RU2658603C2 (ru) * | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) * | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| EP3679949A1 (en) | 2012-08-31 | 2020-07-15 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AU2013312211B2 (en) | 2012-09-07 | 2018-03-29 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
| US9676859B2 (en) * | 2012-11-09 | 2017-06-13 | Transgene Sa | In vitro generation of dendritic cells by exposure to an anti-CSF1-R antibody |
| KR20150140752A (ko) | 2013-04-12 | 2015-12-16 | 모르포시스 아게 | M-csf를 표적으로 하는 항체 |
| AR095882A1 (es) * | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| JP6590810B2 (ja) * | 2013-12-24 | 2019-10-16 | ヤンセン ファーマシューティカ エヌブイ | 抗ｖｉｓｔａ抗体および断片 |
| HRP20181849T1 (hr) | 2013-12-24 | 2018-12-28 | Bristol-Myers Squibb Company | Triciklični spojevi kao antikancerogeni agensi |
| EP3998079A1 (en) | 2014-06-06 | 2022-05-18 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| CN106535884A (zh) | 2014-06-06 | 2017-03-22 | 弗雷克萨斯生物科学公司 | 免疫调节剂 |
| JP6964410B2 (ja) | 2014-06-23 | 2021-11-10 | ファイヴ プライム セラピューティクス インク | コロニー刺激因子１受容体（ｃｓｆ１ｒ）に結合する抗体で疾患を治療する方法 |
| PL3215518T3 (pl) | 2014-10-29 | 2021-08-23 | Bicyclerd Limited | Bicykliczne ligandy peptydowe swoiste wobec MT1-MMP |
| HUE054012T2 (hu) | 2014-10-29 | 2021-08-30 | Five Prime Therapeutics Inc | Kombinációs terápia rák ellen |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| BR112017008809A2 (pt) | 2014-11-05 | 2017-12-19 | Flexus Biosciences Inc | agentes imunorreguladores |
| UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| PT3221363T (pt) | 2014-11-21 | 2020-07-23 | Bristol Myers Squibb Co | Anticorpos contra cd73 e utilizações dos mesmos |
| WO2016106180A1 (en) | 2014-12-22 | 2016-06-30 | Five Prime Therapeutics, Inc. | Anti-csf1r antibodies for treating pvns |
| AR103232A1 (es) | 2014-12-22 | 2017-04-26 | Bristol Myers Squibb Co | ANTAGONISTAS DE TGFbR |
| CN116731176A (zh) | 2014-12-23 | 2023-09-12 | 百时美施贵宝公司 | 针对tigit的抗体 |
| US10983128B2 (en) | 2015-02-05 | 2021-04-20 | Bristol-Myers Squibb Company | CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy |
| ES2789331T3 (es) | 2015-03-02 | 2020-10-26 | Rigel Pharmaceuticals Inc | Inhibidores de TGF-beta |
| AR104176A1 (es) | 2015-04-03 | 2017-07-05 | Bristol Myers Squibb Co | Inhibidores de ido (indolamina-2,3-dioxigenasa) |
| TW201642897A (zh) | 2015-04-08 | 2016-12-16 | Ｆ 星生物科技有限公司 | Ｈｅｒ２結合劑治療 |
| MX388015B (es) * | 2015-04-13 | 2025-03-19 | Five Prime Therapeutics Inc | Un anticuerpo anti-csf1r y al menos un agente inmuno-estimulador para usarse en el tratamiento de cáncer. |
| ES2815683T3 (es) | 2015-05-11 | 2021-03-30 | Bristol Myers Squibb Co | Compuestos tricíclicos como agentes antineoplásicos |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| WO2016183115A1 (en) | 2015-05-12 | 2016-11-17 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
| KR20190080992A (ko) | 2015-05-21 | 2019-07-08 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| US9644032B2 (en) | 2015-05-29 | 2017-05-09 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| US20180222985A1 (en) * | 2015-06-24 | 2018-08-09 | Hoffmann-La Roche Inc. | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| EA201890162A1 (ru) | 2015-06-29 | 2018-07-31 | Бристол-Маерс Сквибб Компани | Антитела к cd40 с повышенной агонистической активностью |
| JP2018526344A (ja) | 2015-07-28 | 2018-09-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｇｆベータ受容体アンタゴニスト |
| US20180250303A1 (en) | 2015-08-25 | 2018-09-06 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| KR102677543B1 (ko) * | 2015-09-16 | 2024-06-24 | 아블렉시스, 엘엘씨 | 항-cd115 항체 |
| US10584160B2 (en) | 2015-09-23 | 2020-03-10 | Bristol-Myers Squibb Company | Glypican-3-binding fibronectin based scaffold molecules |
| SG11201803817PA (en) | 2015-11-19 | 2018-06-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| JP6856648B2 (ja) | 2015-12-15 | 2021-04-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｘｃｒ４受容体アンタゴニスト |
| WO2017152085A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| MX2018012469A (es) | 2016-04-15 | 2019-07-04 | Immunext Inc | Anticuerpos vista antihumanos y uso de los mismos. |
| MA44723A (fr) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics Inc | Anticorps agonistes se liant au cd40 humain et leurs utilisations |
| CN105820250B (zh) | 2016-04-29 | 2019-04-30 | 中国人民解放军第四军医大学 | 一种抗basigin人源化抗体及其应用 |
| KR20190004742A (ko) | 2016-05-04 | 2019-01-14 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
| CN109414421A (zh) | 2016-05-04 | 2019-03-01 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
| US10323004B2 (en) | 2016-05-04 | 2019-06-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| KR20190003686A (ko) | 2016-05-04 | 2019-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
| KR20190003685A (ko) | 2016-05-04 | 2019-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| JP6683020B2 (ja) | 2016-06-01 | 2020-04-15 | 株式会社デンソー | 電力変換装置、及び、これを用いた電動パワーステアリング装置 |
| WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| EP3471754A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 antibodies |
| KR102493282B1 (ko) | 2016-07-14 | 2023-02-01 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체 및 그의 용도 |
| US20190292179A1 (en) | 2016-07-21 | 2019-09-26 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与 |
| CN109843293A (zh) | 2016-08-26 | 2019-06-04 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
| EP3503916A1 (en) | 2016-08-26 | 2019-07-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| JP2018047145A (ja) * | 2016-09-23 | 2018-03-29 | 株式会社三共 | スロットマシン |
| JP2018047144A (ja) * | 2016-09-23 | 2018-03-29 | 株式会社三共 | スロットマシン |
| JP2018047146A (ja) * | 2016-09-23 | 2018-03-29 | 株式会社三共 | スロットマシン |
| JP2018047147A (ja) * | 2016-09-23 | 2018-03-29 | 株式会社三共 | スロットマシン |
| JP2018061577A (ja) * | 2016-10-11 | 2018-04-19 | 株式会社三共 | スロットマシン |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| JP7304287B2 (ja) * | 2016-12-22 | 2023-07-06 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療 |
| WO2018132279A1 (en) | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| EP3570844B1 (en) | 2017-01-20 | 2023-09-06 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
| WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| CA3058944A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| BR112019023855B1 (pt) | 2017-05-12 | 2021-11-30 | Harpoon Therapeutics, Inc | Proteínas de ligação à mesotelina |
| WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| JP7189155B2 (ja) | 2017-05-17 | 2022-12-13 | アーカス バイオサイエンシズ インコーポレイティド | 癌関連障害の治療のためのキナゾリン－ピラゾール誘導体 |
| AU2018269039B2 (en) | 2017-05-19 | 2025-05-15 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| EP3644993B1 (en) | 2017-06-30 | 2023-08-02 | Bristol-Myers Squibb Company | Amorphous and crystalline forms of ido inhibitors |
| CN110997691B (zh) | 2017-07-28 | 2023-11-07 | 百时美施贵宝公司 | 作为抗癌剂的环二核苷酸 |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| WO2019036657A1 (en) | 2017-08-17 | 2019-02-21 | Kyn Therapeutics | AHR INHIBITORS AND USES THEREOF |
| CN111032672B (zh) | 2017-08-31 | 2024-09-13 | 百时美施贵宝公司 | 作为抗癌剂的环二核苷酸 |
| US10947263B2 (en) | 2017-08-31 | 2021-03-16 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019046500A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| EP3681535A1 (en) | 2017-09-13 | 2020-07-22 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
| US11623932B2 (en) | 2017-09-22 | 2023-04-11 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| US11203592B2 (en) | 2017-10-09 | 2021-12-21 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | ANTI-LAP ANTIBODIES AND USES THEREOF |
| US11660311B2 (en) | 2017-10-10 | 2023-05-30 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| ES2997757T3 (en) | 2017-10-16 | 2025-02-18 | Bristol Myers Squibb Co | Cyclic dinucleotides as anticancer agents |
| CN111542544A (zh) | 2017-11-01 | 2020-08-14 | 百时美施贵宝公司 | 用于治疗癌症的免疫刺激性激动性抗体 |
| KR102808367B1 (ko) | 2017-11-06 | 2025-05-14 | 브리스톨-마이어스 스큅 컴퍼니 | Hpk1 억제제로서 유용한 이소푸라논 화합물 |
| JP7471220B2 (ja) | 2017-11-30 | 2024-04-19 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 哺乳動物細胞の培養方法 |
| US20200377571A1 (en) | 2017-12-08 | 2020-12-03 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3732198A1 (en) | 2017-12-27 | 2020-11-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
| WO2019136112A1 (en) | 2018-01-05 | 2019-07-11 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CN120192415A (zh) | 2018-01-12 | 2025-06-24 | 百时美施贵宝公司 | 抗tim3抗体及其用途 |
| CN108276495B (zh) * | 2018-01-24 | 2022-03-18 | 博生吉医药科技(苏州)有限公司 | 靶向csf1r嵌合抗原受体修饰的nk92mi细胞和t细胞及其制法和应用 |
| WO2019147982A1 (en) | 2018-01-26 | 2019-08-01 | Celldex Therapeutics, Inc. | Methods of treating cancer with dendritic cell mobilizing agents |
| AU2019211485B2 (en) | 2018-01-29 | 2025-01-23 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
| IL312674A (en) | 2018-01-29 | 2024-07-01 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
| US10519187B2 (en) | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
| IL276813B2 (en) | 2018-03-05 | 2024-09-01 | Arcus Biosciences Inc | 4-SUBSTITUTED-5-AMINO-OCTAHYDROCYCLOPENTA[c]PYRROLE-5-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMBINATIONS THEREOF AND USE THEREOF IN TREATMENT OF DISEASES |
| WO2019173361A2 (en) | 2018-03-05 | 2019-09-12 | The Schepens Eye Research Institute, Inc. | A therapy for glaucoma and optic neuropathy by targeting colony stimulating factors |
| ES2980374T3 (es) | 2018-03-08 | 2024-10-01 | Bristol Myers Squibb Co | Dinucleótidos cíclicos como agentes anticancerosos |
| JP7510879B2 (ja) | 2018-03-21 | 2024-07-04 | ファイヴ プライム セラピューティクス インク | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
| US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
| EA202092316A1 (ru) | 2018-03-28 | 2021-05-25 | Бристол-Маерс Сквибб Компани | Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения |
| CN112218657A (zh) | 2018-04-12 | 2021-01-12 | 百时美施贵宝公司 | Cd73拮抗剂抗体和pd-1/pd-l1轴拮抗剂抗体的抗癌组合疗法 |
| EP3781162A1 (en) | 2018-04-16 | 2021-02-24 | Arrys Therapeutics, Inc. | Ep4 inhibitors and use thereof |
| IL279489B1 (en) | 2018-06-22 | 2025-06-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| CN112585139B (zh) | 2018-06-27 | 2023-12-01 | 百时美施贵宝公司 | 用作t细胞激活剂的萘啶酮化合物 |
| PE20210469A1 (es) | 2018-06-27 | 2021-03-08 | Bristol Myers Squibb Co | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t |
| EP3817748A4 (en) | 2018-07-06 | 2022-08-24 | Kymera Therapeutics, Inc. | TRICYCLIC CRBN LIGANDS AND USES THEREOF |
| TW202428604A (zh) | 2018-07-09 | 2024-07-16 | 美商戊瑞治療有限公司 | 結合至ilt4的抗體 |
| MX2021000213A (es) | 2018-07-11 | 2021-03-25 | Five Prime Therapeutics Inc | Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acidico. |
| SG11202100267TA (en) | 2018-07-18 | 2021-02-25 | Arcus Biosciences Inc | Solid forms of an azolopyrimidine compound |
| CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
| US12145927B2 (en) | 2018-07-23 | 2024-11-19 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US12059420B2 (en) | 2018-07-23 | 2024-08-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| CN112822999A (zh) * | 2018-09-13 | 2021-05-18 | 豪夫迈·罗氏有限公司 | Csf-1r抗体制剂 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| MX2021003554A (es) | 2018-09-25 | 2021-05-27 | Harpoon Therapeutics Inc | Proteinas de union a dll3 y metodos de uso. |
| JP7465272B2 (ja) | 2018-09-27 | 2024-04-10 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体 |
| JP2022504839A (ja) | 2018-10-10 | 2022-01-13 | ティロス・セラピューティクス・インコーポレイテッド | 抗ｌａｐ抗体変異体及びその使用 |
| US11274150B2 (en) | 2018-11-16 | 2022-03-15 | Bristol-Myers Squibb Company | Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies |
| CN113382998A (zh) | 2018-11-16 | 2021-09-10 | 艾库斯生物科学有限公司 | Arg1和/或arg2的抑制剂 |
| WO2020113233A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2020123444A1 (en) | 2018-12-11 | 2020-06-18 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
| EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
| KR20210137162A (ko) | 2019-03-12 | 2021-11-17 | 아르커스 바이오사이언시즈 인코포레이티드 | 종양유전자-유발 암의 치료 |
| MX2021011320A (es) | 2019-03-19 | 2021-12-10 | Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron | Terapia de combinacion con omomyc y un anticuerpo que se une a pd-1 o a ctla-4 para el tratamiento del cancer. |
| EP3947463A4 (en) | 2019-03-29 | 2022-12-21 | Arcus Biosciences, Inc. | CANCER TREATMENT USING AN IDENTIFIED ADENOSINE IMPRESSION |
| CA3135569A1 (en) | 2019-04-02 | 2020-10-08 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| SG11202110829YA (en) | 2019-04-05 | 2021-10-28 | Kymera Therapeutics Inc | Stat degraders and uses thereof |
| US20230295087A1 (en) | 2019-05-13 | 2023-09-21 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| US12012374B2 (en) | 2019-05-13 | 2024-06-18 | Bristol-Myers Squibb Company | Agonists of ROR GAMMAt |
| MX2021014441A (es) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021026179A1 (en) | 2019-08-06 | 2021-02-11 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| KR20220105631A (ko) | 2019-09-13 | 2022-07-27 | 님버스 새턴 인코포레이티드 | Hpk1 길항제 및 이의 용도 |
| CN114729043A (zh) | 2019-09-19 | 2022-07-08 | 百时美施贵宝公司 | 在酸性pH下结合至VISTA的抗体 |
| CN114430747B (zh) | 2019-09-26 | 2025-02-25 | 豪夫迈·罗氏有限公司 | 抗csf-1r抗体 |
| TWI836159B (zh) | 2019-11-19 | 2024-03-21 | 美商必治妥美雅史谷比公司 | 可作為helios蛋白質抑制劑之化合物 |
| WO2021108528A1 (en) | 2019-11-26 | 2021-06-03 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| KR20220104794A (ko) | 2019-11-26 | 2022-07-26 | 브리스톨-마이어스 스큅 컴퍼니 | (r)-n-(4-클로로페닐)-2-((1s,4s)-4-(6-플루오로퀴놀린-4-일)시클로헥실)프로판아미드의 염/공결정 |
| MX2022007576A (es) | 2019-12-17 | 2022-09-23 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP2023507847A (ja) | 2019-12-23 | 2023-02-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔ細胞アクティベーターとして有用な置換キナゾリニル化合物 |
| JP7653441B2 (ja) | 2019-12-23 | 2025-03-28 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔ細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物 |
| MX2022007372A (es) | 2019-12-23 | 2022-07-12 | Bristol Myers Squibb Co | Compuestos de heteroarilo sustituidos utiles como activadores de celulas t. |
| IL294150A (en) | 2019-12-23 | 2022-08-01 | Kymera Therapeutics Inc | Smarca degraders and uses thereof |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| IL294270A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted piperazine derivatives useful as t cell activators |
| CN116715771A (zh) * | 2019-12-24 | 2023-09-08 | 宝船生物医药科技(上海)有限公司 | 抗csf1r分子及其用途 |
| CA3163988A1 (en) | 2020-01-07 | 2021-07-15 | Germain MARGALL DUCOS | Anti-galectin-9 antibody and uses thereof |
| WO2021178488A1 (en) | 2020-03-03 | 2021-09-10 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| EP4118118A1 (en) | 2020-03-09 | 2023-01-18 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
| WO2021188948A1 (en) | 2020-03-19 | 2021-09-23 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| CN115298165B (zh) | 2020-03-19 | 2024-09-17 | 艾库斯生物科学有限公司 | 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物 |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| EP4132971A1 (en) | 2020-04-09 | 2023-02-15 | Merck Sharp & Dohme LLC | Affinity matured anti-lap antibodies and uses thereof |
| GB202005274D0 (en) | 2020-04-09 | 2020-05-27 | Univ Surrey | Monocyte |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| CA3176246A1 (en) | 2020-06-02 | 2021-12-09 | Arcus Biosciences, Inc. | Antibodies to tigit |
| WO2021247897A1 (en) | 2020-06-03 | 2021-12-09 | Kymera Therapeutics, Inc. | Deuterated irak degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| JP2023530456A (ja) | 2020-06-17 | 2023-07-18 | アーカス バイオサイエンシズ インコーポレイティド | Ｃｄ７３阻害剤の結晶形態及びその使用 |
| AU2021306613A1 (en) | 2020-07-07 | 2023-02-02 | BioNTech SE | Therapeutic RNA for HPV-positive cancer |
| CN116133692A (zh) | 2020-07-30 | 2023-05-16 | 凯麦拉医疗公司 | 治疗突变淋巴瘤的方法 |
| EP4196792A1 (en) | 2020-08-17 | 2023-06-21 | BicycleTX Limited | Bicycle conjugates specific for nectin-4 and uses thereof |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| EP4255895A1 (en) | 2020-12-02 | 2023-10-11 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| EP4271664A4 (en) | 2020-12-30 | 2025-06-11 | Kymera Therapeutics Inc | IRAQ DEGRADING AGENTS AND THEIR USES |
| US20250186539A2 (en) | 2021-01-11 | 2025-06-12 | Bicycletx Limited | Methods for treating cancer |
| MX2023009060A (es) | 2021-02-02 | 2023-09-29 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| EP4288430A1 (en) | 2021-02-02 | 2023-12-13 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| US20240109899A1 (en) | 2021-02-04 | 2024-04-04 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
| EP4291235A4 (en) | 2021-02-12 | 2025-01-08 | Nimbus Saturn Inc | HPK1 ANTAGONISTS AND THEIR USES |
| AU2022220043A1 (en) | 2021-02-15 | 2023-08-31 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| EP4291197A4 (en) | 2021-02-15 | 2024-12-25 | Kymera Therapeutics, Inc. | IRAK4 DEGRADING AGENTS AND THEIR USES |
| JP2024509192A (ja) | 2021-03-05 | 2024-02-29 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
| WO2022197641A1 (en) | 2021-03-15 | 2022-09-22 | Rapt Therapeutics, Inc. | 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases |
| US12071442B2 (en) | 2021-03-29 | 2024-08-27 | Nimbus Saturn, Inc. | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists |
| WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| WO2022216573A1 (en) | 2021-04-05 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
| TWI867287B (zh) | 2021-04-06 | 2024-12-21 | 美商必治妥美雅史谷比公司 | 經吡啶基取代之側氧基異吲哚啉化合物 |
| KR20240007155A (ko) | 2021-04-09 | 2024-01-16 | 님버스 클리오, 인코포레이티드 | Cbl-b 조절제 및 이의 용도 |
| IL307673A (en) | 2021-04-16 | 2023-12-01 | Ikena Oncology Inc | MEK inhibitors and their use |
| JP2024519215A (ja) | 2021-05-07 | 2024-05-09 | カイメラ セラピューティクス， インコーポレイテッド | Ｃｄｋ２分解剤およびそれらの使用 |
| WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
| US20240226115A1 (en) | 2021-05-21 | 2024-07-11 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| AU2022327766A1 (en) | 2021-08-13 | 2023-12-14 | Ludwig-Maximilians-Universität München | Anti-csf1r car expressing lymphocytes for targeted tumor therapy |
| WO2023028238A1 (en) | 2021-08-25 | 2023-03-02 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| EP4392422A1 (en) | 2021-08-25 | 2024-07-03 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| MX2024005138A (es) | 2021-10-29 | 2024-05-13 | Kymera Therapeutics Inc | Degradadores de cinasa-4 asociada al receptor de la interleucina-1 (irak-4) y sintesis de los mismos. |
| AU2022376961A1 (en) | 2021-10-29 | 2024-05-16 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| KR20240144266A (ko) | 2022-01-31 | 2024-10-02 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| CN118946556A (zh) | 2022-02-01 | 2024-11-12 | 阿维纳斯运营公司 | Dgk靶向化合物及其用途 |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
| CN119156228A (zh) | 2022-05-02 | 2024-12-17 | 艾库斯生物科学有限公司 | 抗tigit抗体及其用途 |
| TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Ｍｅｋ抑制劑及其用途 |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| AU2023317741A1 (en) | 2022-08-02 | 2025-03-13 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
| IL318576A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | Pyridoxine-substituted GPR84 antagonists and their uses |
| IL318575A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF |
| CN119654312A (zh) | 2022-08-08 | 2025-03-18 | 百时美施贵宝公司 | 用作t细胞活化剂的取代的四唑基化合物 |
| KR20250046310A (ko) | 2022-08-09 | 2025-04-02 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 3급 아민 치환된 비시클릭 화합물 |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| KR20250080902A (ko) | 2022-10-20 | 2025-06-05 | 아르커스 바이오사이언시즈 인코포레이티드 | Cd73 화합물의 동결건조된 제형 |
| WO2024112894A1 (en) | 2022-11-22 | 2024-05-30 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| WO2024156672A1 (en) | 2023-01-25 | 2024-08-02 | F. Hoffmann-La Roche Ag | Antibodies binding to csf1r and cd3 |
| WO2024233360A1 (en) | 2023-05-05 | 2024-11-14 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024233514A1 (en) | 2023-05-08 | 2024-11-14 | Bristol-Myers Squibb Company | Substituted phenyl oxazolone compounds |
| US20250011441A1 (en) | 2023-05-17 | 2025-01-09 | Syndax Pharmaceuticals, Inc. | Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody |
| US20250011318A1 (en) | 2023-05-25 | 2025-01-09 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024249540A1 (en) | 2023-05-31 | 2024-12-05 | Bristol-Myers Squibb Company | Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins |
| WO2024254227A1 (en) | 2023-06-07 | 2024-12-12 | Bristol-Myers Squibb Company | Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound |
| WO2025030002A2 (en) | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2025064197A1 (en) | 2023-09-02 | 2025-03-27 | Bristol-Myers Squibb Company | Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds |
| EP4568957A1 (en) | 2023-09-02 | 2025-06-18 | Bristol-Myers Squibb Company | Substituted phenyl oxooxazolyl piperidine dione compounds |
| WO2025059245A1 (en) | 2023-09-13 | 2025-03-20 | Bristol-Myers Squibb Company | Substituted oxoisoindolinyl piperidine-2,6-dione compounds |
| WO2025076299A1 (en) | 2023-10-06 | 2025-04-10 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025096539A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096488A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096489A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096494A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096505A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096487A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5606040A (en) * | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5770701A (en) * | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ATE195553T1 (de) | 1992-06-09 | 2000-09-15 | Chiron Corp | Kristallisierung von m-csf |
| DE122004000036I1 (de) | 1992-11-13 | 2005-07-07 | Biogen Idec Inc | Therapeutische Verwendung von chimerischen und markierten Antik¦rper gegen menschlichen B Lymphozyt beschr{nkter Differenzierung antigen f}r die Behandlung von B-Zell-Lymphoma. |
| US5635483A (en) * | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) * | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| UA40577C2 (uk) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
| US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5712374A (en) * | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) * | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| JPH0967400A (ja) | 1995-08-31 | 1997-03-11 | Toray Ind Inc | モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用 |
| IL130864A0 (en) | 1997-03-03 | 2001-01-28 | Bristol Myers Squibb Co | Monoclonal antibodies to human cd6 |
| CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP1019082B2 (en) | 1997-10-02 | 2008-06-04 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| JP4307775B2 (ja) | 1999-10-28 | 2009-08-05 | ゼイェトホサイン・アハリネヤート | Ｃｓｆ−１インヒビターの使用 |
| NZ518764A (en) * | 1999-12-29 | 2004-02-27 | Immunogen Inc | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| ES2345885T3 (es) | 2002-11-15 | 2010-10-05 | Novartis Vaccines And Diagnostics, Inc. | Metodos para prevenir y tratar metastasis de cancer y perdida de hueso asociada con la metastasis de cancer. |
| GB0325836D0 (en) | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
| ES2534185T3 (es) * | 2003-11-06 | 2015-04-20 | Seattle Genetics, Inc. | Compuestos de monometilvalina conjugados con anticuerpos |
| EP2287310B1 (en) | 2004-07-22 | 2015-05-06 | Five Prime Therapeutics, Inc. | Compositions and methods using MGD-CSF in disease treatment |
| TW200714290A (en) | 2005-03-08 | 2007-04-16 | Pharmacia & Upjohn Co Llc | Anti-M-CSF antibody compositions having reduced levels of endotoxin |
| BRPI0619586A2 (pt) | 2005-12-09 | 2018-08-28 | Seattle Genetics Inc | método para o tratamento ou prevenção de um distúrbio associado com cd40 |
| JP5580535B2 (ja) | 2006-01-05 | 2014-08-27 | ノバルティス アーゲー | 癌転移および癌転移に関連する骨量減少を予防および処置するための方法 |
| US20070280935A1 (en) | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| JP2010512421A (ja) | 2006-12-12 | 2010-04-22 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９の合成アゴニスト |
| US20100119457A1 (en) | 2007-03-30 | 2010-05-13 | Helmut Lenz | Composition of labeled and non-labeled monoclonal antibodies |
| WO2008153926A2 (en) | 2007-06-05 | 2008-12-18 | Yale University | Inhibitors of receptor tyrosine kinases and methods of use thereof |
| PL2188313T3 (pl) | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Białka wiążące ludzki antygen c-fms |
| RU2547586C2 (ru) | 2008-03-14 | 2015-04-10 | Трансжене С.А. | Антитело против csf-1r |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| US20110044894A1 (en) | 2008-03-26 | 2011-02-24 | Cellerant Therapeutics, Inc. | Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof |
| RU2017132160A (ru) | 2008-12-09 | 2019-02-08 | Дженентек, Инк. | Антитела к pd-l1 и их применение для усиления функции t-клеток |
| ES2829423T3 (es) | 2009-04-20 | 2021-05-31 | Kyowa Kirin Co Ltd | Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo |
| SMT201700487T1 (it) | 2009-11-24 | 2017-11-15 | Medimmune Ltd | Agenti leganti direzionati contro b7-h-1 |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| US9221910B2 (en) * | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| BR112012020372A8 (pt) | 2010-03-05 | 2018-01-02 | Hoffmann La Roche | anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| MX2012012790A (es) | 2010-05-04 | 2013-02-15 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| JP5798404B2 (ja) | 2010-08-31 | 2015-10-21 | 日東電工株式会社 | 極板保護用粘着テープ |
| US9243066B2 (en) | 2011-07-18 | 2016-01-26 | University Of Melbourne | Use of M-CSF antibodies in the treatment of osteoarthritis or pain |
| US9139652B2 (en) | 2011-10-21 | 2015-09-22 | Transgene Sa | Method for increasing M1 macrophages in a patient |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| JP6416630B2 (ja) | 2012-02-06 | 2018-10-31 | ジェネンテック， インコーポレイテッド | Ｃｓｆ１ｒ阻害剤を用いるための組成物及び方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| JP6217638B2 (ja) | 2012-07-24 | 2017-10-25 | 日立金属株式会社 | ターゲット材およびその製造方法 |
| EP3679949A1 (en) | 2012-08-31 | 2020-07-15 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US9676859B2 (en) | 2012-11-09 | 2017-06-13 | Transgene Sa | In vitro generation of dendritic cells by exposure to an anti-CSF1-R antibody |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
-
2010
- 2010-12-07 ES ES15168902T patent/ES2722300T3/es active Active
- 2010-12-07 TW TW099142677A patent/TWI422388B/zh active
- 2010-12-07 PH PH1/2012/500881A patent/PH12012500881A1/en unknown
- 2010-12-07 HR HRP20160131TT patent/HRP20160131T1/hr unknown
- 2010-12-07 PT PT15168902T patent/PT2949670T/pt unknown
- 2010-12-07 SG SG2012042313A patent/SG181589A1/en unknown
- 2010-12-07 WO PCT/EP2010/069090 patent/WO2011070024A1/en active Application Filing
- 2010-12-07 CN CN201080063488.2A patent/CN102791738B/zh active Active
- 2010-12-07 KR KR1020127017818A patent/KR101434070B1/ko active Active
- 2010-12-07 EP EP10794936.4A patent/EP2510010B1/en active Active
- 2010-12-07 NZ NZ599516A patent/NZ599516A/xx unknown
- 2010-12-07 HU HUE15168902 patent/HUE044179T2/hu unknown
- 2010-12-07 LT LTEP15168902.3T patent/LT2949670T/lt unknown
- 2010-12-07 SI SI201031097T patent/SI2510010T1/sl unknown
- 2010-12-07 MX MX2012006553A patent/MX2012006553A/es active IP Right Grant
- 2010-12-07 RS RS20160074A patent/RS54596B1/en unknown
- 2010-12-07 DK DK15168902.3T patent/DK2949670T3/da active
- 2010-12-07 JP JP2012542522A patent/JP5677451B2/ja active Active
- 2010-12-07 SI SI201031886T patent/SI2949670T1/sl unknown
- 2010-12-07 US US12/962,445 patent/US8999327B2/en active Active
- 2010-12-07 CA CA2780692A patent/CA2780692C/en active Active
- 2010-12-07 DK DK10794936.4T patent/DK2510010T3/en active
- 2010-12-07 PL PL15168902T patent/PL2949670T3/pl unknown
- 2010-12-07 PT PT107949364T patent/PT2510010E/pt unknown
- 2010-12-07 ES ES10794936.4T patent/ES2557454T3/es active Active
- 2010-12-07 AU AU2010329934A patent/AU2010329934B2/en active Active
- 2010-12-07 RS RS20190530A patent/RS58693B1/sr unknown
- 2010-12-07 HU HUE10794936A patent/HUE026201T2/en unknown
- 2010-12-07 CN CN201510673059.1A patent/CN105218672A/zh active Pending
- 2010-12-07 PL PL10794936T patent/PL2510010T3/pl unknown
- 2010-12-07 BR BR112012013717A patent/BR112012013717B1/pt active IP Right Grant
- 2010-12-07 RU RU2012128651/10A patent/RU2565541C2/ru active
- 2010-12-07 MY MYPI2012002592A patent/MY159679A/en unknown
- 2010-12-07 MA MA34923A patent/MA34780B1/fr unknown
- 2010-12-07 EP EP15168902.3A patent/EP2949670B1/en active Active
- 2010-12-07 PE PE2012000793A patent/PE20121398A1/es active IP Right Grant
- 2010-12-09 AR ARP100104542A patent/AR079333A1/es active IP Right Grant
-
2012
- 2012-04-26 CR CR20120215A patent/CR20120215A/es unknown
- 2012-05-03 IL IL219595A patent/IL219595A/en active IP Right Grant
- 2012-05-23 ZA ZA2012/03782A patent/ZA201203782B/en unknown
- 2012-05-30 CO CO12090413A patent/CO6541621A2/es unknown
- 2012-06-07 MX MX2014008680A patent/MX353706B/es unknown
- 2012-06-08 CL CL2012001547A patent/CL2012001547A1/es unknown
- 2012-06-08 EC ECSP12011964 patent/ECSP12011964A/es unknown
-
2013
- 2013-03-25 HK HK16107619.8A patent/HK1219739A1/zh unknown
-
2014
- 2014-10-29 US US14/527,097 patent/US9499624B2/en active Active
- 2014-12-25 JP JP2014262097A patent/JP2015120697A/ja active Pending
-
2015
- 2015-03-06 US US14/640,202 patent/US9499626B2/en active Active
- 2015-03-06 US US14/640,183 patent/US9499625B2/en active Active
- 2015-08-12 AU AU2015213308A patent/AU2015213308B2/en active Active
-
2016
- 2016-02-18 CY CY20161100138T patent/CY1117331T1/el unknown
- 2016-10-13 US US15/292,710 patent/US9663580B2/en active Active
-
2017
- 2017-02-08 JP JP2017021279A patent/JP2017123850A/ja active Pending
- 2017-04-17 US US15/489,519 patent/US9879085B2/en active Active
- 2017-12-21 US US15/849,743 patent/US10072087B2/en active Active
-
2018
- 2018-01-19 US US15/875,530 patent/US10077314B1/en active Active
- 2018-08-06 US US16/055,947 patent/US10287358B2/en active Active
-
2019
- 2019-03-25 US US16/362,962 patent/US20190300614A1/en not_active Abandoned
- 2019-04-24 HR HRP20190762TT patent/HRP20190762T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012001547A1 (es) | Anticuerpo ligante de csf-1r humano; composicion farmaceutica que lo comprende; acido nucleico que lo codifica; vector de expresion recombinante; celula procariotica o eucariotica transformada; metodo de produccion; y su uso para tratar cancer. | |
| CL2012001649A1 (es) | Anticuerpo de unión a her3/erb-3/c-erbb-3/c-erbb3 humano; acido nucleico que lo codifica; vector de expresión recombinante; célula huésped procariótica o eucariótica transformada que comprende dicho vector; método de producción de dicho anticuerpo; composición farmacéutica que lo comprende; y su uso para tratar cáncer. | |
| CL2013000566A1 (es) | Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
| CL2013001625A1 (es) | Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa. | |
| CL2014000631A1 (es) | Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
| CL2011002611A1 (es) | Anticuerpo aislado anti-cadherina-17; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; inmunoconjugado que lo comprende; composicion que lo comprende; y su uso para tratar o prevenir una enfermedad asociada con celulas objetivo que expresan cadherina-17. | |
| CL2013000545A1 (es) | Anticuerpo anti-ox40; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar cancer o una enfermedad autoinmune. | |
| CL2007001488A1 (es) | Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina. | |
| CL2013000074A1 (es) | Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos. | |
| CL2013000369A1 (es) | Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer. | |
| CL2014001055A1 (es) | Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso. | |
| CL2007002987A1 (es) | Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para tratar enfermedades relacionadas con notch3. | |
| CL2011000672A1 (es) | Anticuerpo que se une a il-17 humana; acido nucleico que lo codifica; vector de expresion; linea celular; metodo de produccion; composicion farmaceutica que lo comprende y su uso para tratar artritis reumatoidea entre otras enfermedades. | |
| CL2011001285A1 (es) | Anticuerpo que se une a la angiopoyetina-2 humana (ang-2 o ang2 o angpt2); acido nucleico que lo codifica; vector de expresion recombinante; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar cancer. | |
| CL2013001279A1 (es) | Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso. | |
| CL2011002784A1 (es) | Anticuerpo anti-egfl7; acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion que lo comprende, y su uso para tratar un tumor, cancer o un trastorno proliferativo. | |
| CL2011002039A1 (es) | Anticuerpo humanizado que se une al cd19 humano; acido nucleico aislado que codifica dicho anticuerpo; vector y celula huesped; composicion e inmunoconjugado; metodo para inhibir el crecimiento de celulas de tumor que expresan cd19. | |
| CL2013003336A1 (es) | Anticuerpo anti-cgrp humano; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica y diagnostica que lo comprende; y su uso terapéutico | |
| CL2015003090A1 (es) | Proteínas de unión específicas y sus usos. | |
| CL2014000958A1 (es) | Polipeptidos de anticuerpos que antagonizan cd4ol; acido nucleico que codifica dicho anticuerpo; vector y célula huesped que la comprenden; composicion farmacéutica; uso de dichos polipéptidos para tratar enfermedad inmunitaria. | |
| CL2007003623A1 (es) | Proteina de enlace multivalente monocatenaria con funcion efectora; acido nucleico que la codifica; vector y celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y metodo para tratar trastornos proliferativos. | |
| CL2011002482A1 (es) | Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer | |
| CL2014001054A1 (es) | Proteina de enlace que se une al factor de necrosis tumoral alfa (tnf-alfa); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; su uso para tratar un trastorno asociado a tnf-alfa; y metodo para determinar la presencia de tnf-alfa en una muestra. | |
| CL2009000459A1 (es) | Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso. | |
| BR112014004168A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção |